The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 01, 2013

Filed:

Apr. 28, 2012
Applicants:

Caroline Joy Springer, Sutton, GB;

Dan Niculescu-duvaz, Sutton, GB;

Ion Niculescu-duvaz, Sutton, GB;

Richard Marais, London, GB;

Bartholomeus Marinus Josephus Marie Suijkerbuijk, Sutton, GB;

Alfonso Zambon, Sutton, GB;

Arnaud Nourry, Le Man Cedex 9, FR;

Delphine Menard, Sutton, GB;

Inventors:

Caroline Joy Springer, Sutton, GB;

Dan Niculescu-Duvaz, Sutton, GB;

Ion Niculescu-Duvaz, Sutton, GB;

Richard Marais, London, GB;

Bartholomeus Marinus Josephus Marie Suijkerbuijk, Sutton, GB;

Alfonso Zambon, Sutton, GB;

Arnaud Nourry, Le Man Cedex 9, FR;

Delphine Menard, Sutton, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4985 (2006.01); A61K 31/5377 (2006.01); C07D 471/14 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.


Find Patent Forward Citations

Loading…